PLGA nanoparticles loaded with KMP-11 stimulate innate immunity and induce the killing of Leishmania

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 9, Issue 7, 2013, Pages 985-995

  Santos, Diego M ^a,e   Carneiro, Marcia W ^a   de Moura, Tatiana R ^a,e   Soto, Manuel ^b   Luz, Nívea F ^a   Prates, Deboraci B ^a,f   Irache, Juan Manuel ^c   Brodskyn, Claudia ^a,d   Barral, Aldina ^a,d   Barral Netto, Manoel ^a,d   Espuelas, Socorro ^c   Borges, Valéria M ^a   De Oliveira, Camila I ^a,d  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

^d Instituto de Investigação em Imunologia   (Brazil)

^e FEDERAL UNIVERSITY OF SERGIPE   (Brazil)

^f FEDERAL UNIVERSITY OF BAHIA   (Brazil)

Author keywords

Innate response; Leishmania; Macrophage; Nanoparticle; PLGA

Indexed keywords

CLINICAL APPLICATION; INNATE IMMUNE RESPONSE; INNATE RESPONSE; LEISHMANIA; MEMBRANE PROTEINS; PARASITIC INFECTIONS; PLGA; PLGA NANOPARTICLES;

BIOLOGICAL MEMBRANES; COPOLYMERS; ELECTRIC LOAD MANAGEMENT; IMMUNE SYSTEM; MACROPHAGES; NITRIC OXIDE; OXYGEN;

NANOPARTICLES;

ANTILEISHMANIAL AGENT; CXCL1 CHEMOKINE; INFLAMMASOME; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 6; KINETOPLASTID MEMBRANE PROTEIN 11; LEISHMANIA VACCINE; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; POLYGLACTIN; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; INNATE IMMUNITY; LEISHMANIA; LEISHMANIA BRAZILIENSIS; MACROPHAGE; MOUSE; NEUTROPHIL; NONHUMAN; PARASITE LOAD;

KINETOPLASTIDA; LEISHMANIA BRAZILIENSIS;

INNATE RESPONSE; LEISHMANIA; MACROPHAGE; NANOPARTICLE; PLGA;

ANIMALS; CELL DEATH; CHEMOKINES; DNA; FEMALE; IMMUNITY, INNATE; INFLAMMASOMES; LACTIC ACID; LEISHMANIA; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED BALB C; NANOPARTICLES; NITRIC OXIDE; POLYGLYCOLIC ACID; PROTOZOAN PROTEINS; SUPEROXIDES;

EID: 84884285108     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2013.04.003     Document Type: Article

References (50)

1. Storni T., Kundig T.M., Senti G., Johansen P. Immunity in response to particulate antigen-delivery systems. Adv Drug Deliv Rev 2005, 57:333-355.
2. Panyam J., Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003, 55:329-347.
3. Reddy S.T., Rehor A., Schmoekel H.G., Hubbell J.A., Swartz M.A. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J Control Release 2006, 112:26-34.
4. Okada H., Toguchi H. Biodegradable microspheres in drug delivery. Crit Rev Ther Drug Carrier Syst 1995, 12:1-99.
5. Carcaboso A.M., Hernandez R.M., Igartua M., Rosas J.E., Patarroyo M.E., Pedraz J.L. Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles. Vaccine 2004, 22:1423-1432.
6. Chong C.S.W., Cao M., Wong W.W., Fischer K.P., Addison W.R., Kwon G.S., et al. Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery. J Control Release 2005, 102:85-99.
7. Hamdy S., Molavi O., Ma Z., Haddadi A., Alshamsan A., Gobti Z., et al. Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity. Vaccine 2008, 26:5046-5057.
8. Doroud D., Zahedifard F., Vatanara A., Najafabadi A.R., Rafati S. Cysteine proteinase type I, encapsulated in solid lipid nanoparticles induces substantial protection against Leishmania major infection in C57BL/6 mice. Parasite Immunol 2011, 33:335-348.
9. Doroud D., Zahedifard F., Vatanara A., Najafabadi A.R., Taslimi Y., Vahabpour R., et al. Delivery of a cocktail DNA vaccine encoding cysteine proteinases type I, II and III with solid lipid nanoparticles potentiate protective immunity against Leishmania major infection. J Control Release 2011, 153:154-162.
10. Tafaghodi M., Khamesipour A., Jaafari M.R. Immunization against leishmaniasis by PLGA nanospheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN. Parasitol Res 2011, 108:1265-1273.
11. Jardim A., Funk V., Caprioli R.M., Olafson R.W. Isolation and structural characterization of the Leishmania donovani kinetoplastid membrane protein-11, a major immunoreactive membrane glycoprotein. Biochem J 1995, 305:307-313.
12. Santos D.M., Carneiro M.W., de Moura T.R., Fukutani K., Clarencio J., Soto M., et al. Towards development of novel immunization strategies against leishmaniasis using PLGA nanoparticles loaded with kinetoplastid membrane protein-11. Int J Nanomedicine 2012, 7:2115-2127.
13. Thomas M.C., Garcia-Perez J.L., Alonso C., Lopez M.C. Molecular characterization of KMP11 from Trypanosoma cruzi: a cytoskeleton-associated protein regulated at the translational level. DNA Cell Biol 2000, 19:47-57.
14. Jensen A.T., Gasim S., Ismail A., Gaafar A., Kurtzhals J.A., Kemp M., et al. Humoral and cellular immune responses to synthetic peptides of the Leishmania donovani kinetoplastid membrane protein-11. Scand J Immunol 1998, 48:103-109.
15. Basu R., Bhaumik S., Basu J.M., Naskar K., De T., Roy S. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J Immunol 2005, 174:7160-7171.
16. Basu R., Roy S., Walden P. HLA class I-restricted T cell epitopes of the kinetoplastid membrane protein-11 presented by Leishmania donovani-infected human macrophages. J Infect Dis 2007, 195:1373-1380.
17. Bhaumik S., Basu R., Sen S., Naskar K., Roy S. KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major. Vaccine 2009, 27:1306-1316.
18. Bittencourt A., Barral-Netto M. Leishmaniasis. Tropical Pathology 1995, 597-651. Springer, Berlin. 2nd ed. W.S.G. Doerr (Ed.).
19. del Barrio G.G., Novo F.J., Irache J.M. Loading of plasmid DNA into PLGA microparticles using TROMS (Total Recirculation One-Machine System): evaluation of its integrity and controlled release properties. J Control Release 2003, 86:123-130.
20. San Roman B., Irache J.M., Gomez S., Tsapis N., Gamazo C., Espuelas M.S. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology. Eur J Pharm Biopharm 2008, 70:98-108.
21. de Moura T.R., Novais F.O., Oliveira F., Clarencio J., Noronha A., Barral A., et al. Toward a novel experimental model of infection to study American cutaneous leishmaniasis caused by Leishmania braziliensis. Infect Immun 2005, 73:5827-5834.
22. Miranda K.M., Espey M.G., Wink D.A. A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 2001, 5:62-71.
23. Prates D.B., Araújo-Santos T., Luz N.F., Andrade B.B., França-Costa J., Afonso L., et al. Lutzomyia longipalpis saliva drives apoptosis and enhances parasite burden in neutrophils. J Leukoc Biol 2011, 90:575-582.
24. Svensjo E., Saraiva E.M., Amendola R.S., Barja-Fidalgo C., Bozza M.T., Lerner E.A., et al. Maxadilan, the Lutzomyia longipalpis vasodilator, drives plasma leakage via PAC1-CXCR1/2-pathway. Microvasc Res 2012, 83:185-193.
25. van Zandbergen G., Klinger M., Mueller A., Dannenberg S., Gebert A., Solbach W., et al. Cutting edge: neutrophil granulocyte serves as a vector for Leishmania entry into macrophages. J Immunol 2004, 173:6521-6525.
26. Lonez C., Vandenbranden M., Ruysschaert J.M. Cationic lipids activate intracellular signaling pathways. Adv Drug Deliv Rev 2012, 64:1749-1758.
27. Sharp F.A., Ruane D., Claass B., Creagh E., Harris J., Malyala P., et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci U S A 2009, 106:870-875.
28. Elamanchili P., Diwan M., Cao M., Samuel J. Characterization of poly(d, l-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine 2004, 22:2406-2412.
29. Audran R., Peter K., Dannull J., Men Y., Scandella E., Groettrup M., et al. Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro. Vaccine 2003, 21:1250-1255.
30. Lutsiak M.E., Kwon G.S., Samuel J. Biodegradable nanoparticle delivery of a Th2-biased peptide for induction of Th1 immune responses. J Pharm Pharmacol 2006, 58:739-747.
31. Fukuhara Y., Naoi T., Ogawa Y., Nishikawa M., Takakura Y. Plasmid DNA uptake and subsequent cellular activation characteristics in human monocyte-derived cells in primary culture. J Pharm Sci 2007, 96:1576-1584.
32. Khouri R., Novais F., Santana G., de Oliveira C.I., Vannier dos Santos M.A., Barral A., et al. DETC induces Leishmania parasite killing in human in vitro and murine in vivo models: a promising therapeutic alternative in leishmaniasis. PLoS One 2010, 5:e14394.
33. Yan W., Chen W., Huang L. Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines. Mol Immunol 2007, 44:3672-3681.
34. Nicolete R., dos Santos D.F., Faccioli L.H. The uptake of PLGA micro or nanoparticles by macrophages provokes distinct in vitro inflammatory response. Int Immunopharmacol 2011, 11:1557-1563.
35. Dos Santos D.F., Bitencourt C.D., Gelfuso G.M., Pereira P.A., de Souza P.R., Sorgi C.A., et al. Biodegradable microspheres containing leukotriene B(4) and cell-free antigens from Histoplasma capsulatum activate murine bone marrow-derived macrophages. Eur J Pharm Sci 2011, 18:580-581.
36. Liew F.Y., Li Y., Millott S. Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide. J Immunol 1990, 145:4306-4310.
37. Theodos C.M., Povinelli L., Molina R., Sherry B., Titus R.G. Role of tumor necrosis factor in macrophage leishmanicidal activity in vitro and resistance to cutaneous leishmaniasis in vivo. Infect Immun 1991, 59:2839-2842.
38. Assreuy J., Cunha F.Q., Epperlein M., Noronha-Dutra A., O'Donnell C.A., Liew F.Y., et al. Production of nitric oxide and superoxide by activated macrophages and killing of Leishmania major. Eur J Immunol 1994, 24:672-676.
39. Bozic C.R., Kolakowski L.F., Gerard N.P., Garcia-Rodriguez C., von Uexkull-Guldenband C., Conklyn M.J., et al. Expression and biologic characterization of the murine chemokine KC. J Immunol 1995, 154:6048-6057.
40. Kobayashi Y. The role of chemokines in neutrophil biology. Front Biosci 2008, 13:2400-2407.
41. Rollins B.J., Walz A., Baggiolini M. Recombinant human MCP-1/JE induces chemotaxis, calcium flux, and the respiratory burst in human monocytes. Blood 1991, 78:1112-1116.
42. Ritter U., Moll H. Monocyte chemotactic protein-1 stimulates the killing of leishmania major by human monocytes, acts synergistically with IFN-gamma and is antagonized by IL-4. Eur J Immunol 2000, 30:3111-3120.
43. Ferrari D., Chiozzi P., Falzoni S., Hanau S., Di Virgilio F. Purinergic modulation of interleukin-1 beta release from microglial cells stimulated with bacterial endotoxin. J Exp Med 1997, 185:579-582.
44. Martinon F., Petrilli V., Mayor A., Tardivel A., Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237-241.
45. Eisenbarth S.C., Colegio O.R., O'Connor W., Sutterwala F.S., Flavell R.A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008, 453:1122-1126.
46. Meunier E., Coste A., Olagnier D., Authier H., Lefevre L., Dardenne C., et al. Double-walled carbon nanotubes trigger IL-1beta release in human monocytes through Nlrp3 inflammasome activation. Nanomedicine 2012, 8:987-995.
47. Schroder K., Tschopp J. The inflammasomes. Cell 2010, 140:821-832.
48. Hornung V., Ablasser A., Charrel-Dennis M., Bauernfeind F., Horvath G., Caffrey D.R., et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 2009, 458:514-518.
49. Fernandes-Alnemri T., Yu J.W., Datta P., Wu J., Alnemri E.S. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 2009, 458:509-513.
50. Rathinam V.A., Jiang Z., Waggoner S.N., Sharma S., Cole L.E., Waggoner L., et al. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol 2010, 11:395-402.